Revelation Biosciences, Inc. Common Stock (REVB) is a publicly traded Healthcare sector company. As of November 5, 2026, REVB trades at $3.64 with a market cap of $2.34M and a P/E ratio of -0.04. REVB moved -9.17% today. Year to date, REVB is -84.78%; over the trailing twelve months it is -88.18%. Its 52-week range spans $3.08 to $313.39. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces REVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for REVB shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $3.64 |
| Market Cap | $2.34M |
| P/E Ratio | -0.04 |
| EPS | $-19.37 |
| Dividend Yield | 0.00% |
| 52-Week High | $313.39 |
| 52-Week Low | $3.08 |
| Volume | 15.03K |
| Avg Volume | 0 |
| Revenue (TTM) | $165.99K |
| Net Income | $-10.75M |
| Gross Margin | 0.00% |
1 analysts cover REVB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.